A First-in-Human, Ascending Dose, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of UKK-0018 in Peanut Allergic Individuals
Status: Recruiting
Location: See all (5) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 55
Healthy Volunteers: f
View:
• Adults 18-55 years old
• documented history of physician-diagnosed peanut allergy
• positive skin prick test (SPT)
• screening DBPCFC peanut protein
• contraception use should be consistent with local regulations
• capable of providing signed written informed consent
Locations
Other Locations
Australia
Flinders Medical Center
NOT_YET_RECRUITING
Bedford Park
Royal Prince Alfred Hospital
NOT_YET_RECRUITING
Camperdown
The Royal Melbourne Hospital
NOT_YET_RECRUITING
Fitzroy
Fiona Stanley Hospital
NOT_YET_RECRUITING
Perth
New Zealand
Pacific Clinical Research Network - Auckland
RECRUITING
Takapuna
Contact Information
Primary
Clinical Development Officer
sharron@ukko.us
+1 503 915 1400
Time Frame
Start Date: 2026-02-18
Estimated Completion Date: 2027-11-01
Participants
Target number of participants: 40
Treatments
Experimental: UKK-0018
UKK0018 is an immunotherapeutic for the treatment of peanut allergies
Related Therapeutic Areas
Sponsors
Leads: Ukko Inc